The updated Medscheme specialised drug list for 2023 has been published

By Staff Writer

May 12, 2023

Reimbursement is still dependent on authorisation and benefit limits.

Some drugs included:
ANTIHEMORRHAGICS
Hemlibra

CARDIOVASCULAR SYSTEM
Volibris

DERMATOLOGICALS
Dupixent

ANTIVIRALS FOR SYSTEMIC USE
Epclusa

ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy

IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya

DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair

Reference url

Recent Posts

cervical self-sampling methods
   

Cervical Self-Sampling Methods: Overcoming Barriers

🤔 *Are traditional cervical screenings leaving underserved communities behind?*
A recent study highlights the barriers faced by these groups and unveils a promising alternative: cervical self-sampling methods. These less invasive options empower patients, ensuring greater choice and autonomy while potentially increasing screening rates.

Check out the article to learn how self-sampling could revolutionize access to cervical cancer prevention!

#SyenzaNews #HealthEconomics #HealthcareInnovation

digital HIV self-testing
        

Cost-Effectiveness of Digital HIV Self-Testing

💡 Is digital innovation the key to enhancing HIV testing in high-prevalence regions?

A recent study reveals that digital HIV self-testing (HIVST) not only proves cost-effective but significantly improves care linkage, particularly among populations with higher HIV test-positivity rates. This data-driven approach could reshape public health strategies in Malawi, South Africa, and Brazil!

Jump into the findings and implications for policy and health equity in our latest article!

#SyenzaNews #digitalhealth #HealthEconomics #costeffectiveness

gene therapy sickle cell
            

NICE Approves Gene Therapy for Sickle Cell: A Breakthrough in Treatment and Health Equity

🌟 Are we on the brink of a cure for sickle cell disease?

The recent approval of a one-off gene therapy by NICE offers hope for individuals suffering from severe sickle cell disease, addressing both health outcomes and economic disparities. This breakthrough not only promises to enhance quality of life but also tackles the socio-economic challenges associated with the disease.

Jump into the full article to learn more about the implications of this gene therapy and its potential impact on the healthcare landscape.

#SyenzaNews #HealthEconomics #HealthcareInnovation #CostEffectiveness

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.